Bupivacaine News and Research

RSS
ICS, Quintiles enter agreement with Pacira to support launch of EXPAREL

ICS, Quintiles enter agreement with Pacira to support launch of EXPAREL

Pacira second quarter total revenues increase to $3.6 million

Pacira second quarter total revenues increase to $3.6 million

FDA extends Pacira's EXPAREL PDUFA goal date by three months

FDA extends Pacira's EXPAREL PDUFA goal date by three months

Positive results from EXPAREL Phase 3 study to be presented at ASCRS Annual Scientific Meeting

Positive results from EXPAREL Phase 3 study to be presented at ASCRS Annual Scientific Meeting

Pacira Pharmaceuticals reports net loss of $9.8 million for first quarter 2011

Pacira Pharmaceuticals reports net loss of $9.8 million for first quarter 2011

Pacira to present EXPAREL data in postsurgical pain at two medical meetings

Pacira to present EXPAREL data in postsurgical pain at two medical meetings

Top-line results from DURECT's ELADUR Phase II trial in chronic low back pain

Top-line results from DURECT's ELADUR Phase II trial in chronic low back pain

Pacira reports net loss of $7.0 million for quarter ended December 31, 2010

Pacira reports net loss of $7.0 million for quarter ended December 31, 2010

U.S.-Chile collaborate to study new long-acting local anesthetic derived from algae

U.S.-Chile collaborate to study new long-acting local anesthetic derived from algae

Pacira prices initial public offering at $7.00 per share

Pacira prices initial public offering at $7.00 per share

Profectus BioSciences commences GENEVAX IL-12 phase 1 study for HIV

Profectus BioSciences commences GENEVAX IL-12 phase 1 study for HIV

Biomet Biologics completes enrollment in Recover Kit clinical trial for chronic tennis elbow

Biomet Biologics completes enrollment in Recover Kit clinical trial for chronic tennis elbow

Profectus' GENEVAX IL-12 pDNA adjuvant improves vaccine-induced response rate in Phase I HIV study

Profectus' GENEVAX IL-12 pDNA adjuvant improves vaccine-induced response rate in Phase I HIV study

FDA accepts for filing Pacira's EXPAREL NDA for postsurgical pain management

FDA accepts for filing Pacira's EXPAREL NDA for postsurgical pain management

Interleukin-1 plays major role in wound healing

Interleukin-1 plays major role in wound healing

Transforaminal injection of steroids is a viable alternative for lumbar radicular pain surgery

Transforaminal injection of steroids is a viable alternative for lumbar radicular pain surgery

Innocoll submits SPA for phase 3 clinical trial of Cogenzia for adjuvant treatment of infected diabetic foot ulcers

Innocoll submits SPA for phase 3 clinical trial of Cogenzia for adjuvant treatment of infected diabetic foot ulcers

DURECT reports European POSIDUR Phase IIb hysterectomy clinical trial results

DURECT reports European POSIDUR Phase IIb hysterectomy clinical trial results

Hospira signs licensing agreement to develop and market DURECT's POSIDUR

Hospira signs licensing agreement to develop and market DURECT's POSIDUR

Pacira Pharmaceuticals receives $11.25M credit facility from GE Capital, Healthcare Financial Services

Pacira Pharmaceuticals receives $11.25M credit facility from GE Capital, Healthcare Financial Services

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.